title: Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.
abstract: A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin-timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav(®) (Alcon, Fort Worth, USA) and Ganfort(®) (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.
authors.affiliation: Department of Ophthalmology, Semmelweis University, Budapest, Hungary, hgbudapest@gmail.com.
authors.forename: Gábor
authors.initials: G
authors.lastname: Holló
authors.forename: Jouni
authors.initials: J
authors.lastname: Vuorinen
authors.forename: Juhani
authors.initials: J
authors.lastname: Tuominen
authors.forename: Teppo
authors.initials: T
authors.lastname: Huttunen
authors.forename: Auli
authors.initials: A
authors.lastname: Ropo
authors.forename: Norbert
authors.initials: N
authors.lastname: Pfeiffer
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000577:Amides / Q000627:therapeutic use; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D009798:Ocular Hypertension / Q000188:drug therapy*; D011310:Preservatives, Pharmaceutical; D011460:Prostaglandins F / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013999:Timolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D000577:Amides; D004338:Drug Combinations; C571754:Duotrav; C571755:Ganfort; D011310:Preservatives, Pharmaceutical; D011460:Prostaglandins F; C485333:tafluprost; D003008:Cloprostenol; D013999:Timolol